NCT04490239View on ClinicalTrials.gov

Intranasal Heparin Tolerability Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

November 18, 2020

Study Completion Date

November 18, 2020

Conditions
Covid19
Interventions
DRUG

Intranasal heparin sodium (porcine)

Intranasal heparin sodium

Trial Locations (1)

38677-1848

The University of Mississippi National Center for Natural Products Research, University

All Listed Sponsors
lead

Joshua Sharp

OTHER

NCT04490239 - Intranasal Heparin Tolerability Study | Biotech Hunter | Biotech Hunter